Immunotherapy and Prevention of Pancreatic Cancer

Overview

Journal Trends Cancer

Publisher Cell Press

Specialty Oncology

Date 2018 Jun 5

PMID 29860986

Citations 223

Authors

Alexander H Morrison

Katelyn T Byrne

Robert H Vonderheide

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer. In this Review article, we discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of prevention vaccines for this and other cancers.

Citing Articles

Causal relationship and potential common pathogenic mechanisms between hidradenitis suppurativa and related cancer.

Zhu Z, Wang X Discov Oncol. 2025; 16(1):304.

PMID: 40072688 PMC: 11904070. DOI: 10.1007/s12672-025-02075-4.

Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcinoma.

Zhou X, Ba Y, Xu N, Xu H, Zhang Y, Liu L Mol Med. 2025; 31(1):62.

PMID: 39972282 PMC: 11837470. DOI: 10.1186/s10020-024-01049-6.

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.

Louie A, Huntington K, Lee Y, Mompoint J, Wu L, Lee S Am J Cancer Res. 2025; 15(1):286-298.

PMID: 39949937 PMC: 11815385. DOI: 10.62347/ROAT5658.

The miR-1305/KLF5 negative regulatory loop affects pancreatic cancer cell proliferation and apoptosis.

Zhou Y, Tang Y, Huang F, Wang Z, Wen Z, Fang Q Hum Cell. 2025; 38(2):51.

PMID: 39921786 DOI: 10.1007/s13577-025-01173-3.

Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning.

Zhang X, Lin F, Wen Y, Guan K Discov Oncol. 2025; 16(1):96.

PMID: 39873820 PMC: 11775367. DOI: 10.1007/s12672-025-01841-8.

References

Kimura T, McKolanis J, Dzubinski L, Islam K, Potter D, Salazar A . MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2012; 6(1):18-26. PMC: 3536916. DOI: 10.1158/1940-6207.CAPR-12-0275. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Yong C, Dardalhon V, Devaud C, Taylor N, Darcy P, Kershaw M . CAR T-cell therapy of solid tumors. Immunol Cell Biol. 2016; 95(4):356-363. DOI: 10.1038/icb.2016.128. View

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

Cheng G . Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2014; 81:75-93. DOI: 10.1016/j.addr.2014.09.001. View

Le D, Picozzi V, Ko A, Wainberg Z, Kindler H, Wang-Gillam A . Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019; 25(18):5493-5502. PMC: 7376746. DOI: 10.1158/1078-0432.CCR-18-2992. View

Melstrom L, Salazar M, Diamond D . The pancreatic cancer microenvironment: A true double agent. J Surg Oncol. 2017; 116(1):7-15. PMC: 5989710. DOI: 10.1002/jso.24643. View

Steele C, Karim S, Leach J, Bailey P, Upstill-Goddard R, Rishi L . CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2016; 29(6):832-845. PMC: 4912354. DOI: 10.1016/j.ccell.2016.04.014. View

10.

Winograd R, Byrne K, Evans R, Odorizzi P, Meyer A, Bajor D . Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015; 3(4):399-411. PMC: 4390506. DOI: 10.1158/2326-6066.CIR-14-0215. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

13.

Weden S, Klemp M, Gladhaug I, Moller M, Eriksen J, Gaudernack G . Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2010; 128(5):1120-8. DOI: 10.1002/ijc.25449. View

14.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View

15.

Kim J, Bamlet W, Oberg A, Chaffee K, Donahue G, Cao X . Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017; 9(398). PMC: 5727893. DOI: 10.1126/scitranslmed.aah5583. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J . CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014; 74(18):5057-69. PMC: 4182950. DOI: 10.1158/0008-5472.CAN-13-3723. View

18.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

19.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View

20.

Lehtinen M, Paavonen J, Wheeler C, Jaisamrarn U, Garland S, Castellsague X . Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011; 13(1):89-99. DOI: 10.1016/S1470-2045(11)70286-8. View